Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Natera, |
RCV003466330 | SCV007528145 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2024-09-24 | criteria provided, single submitter | clinical testing | The c.171+1G>A variant in SACS is a canonical splice donor site variant predicted to affect pre-mRNA splicing, which may result in an abnormal transcript and altered protein product. This variant is expected to result in nonsense mediated decay, truncation, or a dysfunctional protein product. This variant is rare in the general population with a frequency below the threshold expected for the associated phenotype(s). Given the available evidence, this variant is classified as Likely Pathogenic. |
| PROSPAX |
RCV003466330 | SCV005061939 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2022-01-01 | criteria provided, single submitter | research | |
| Baylor Genetics | RCV003466330 | SCV004209944 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2024-03-25 | criteria provided, single submitter | clinical testing |